Galderma Forecast, price target & analysts
CHF191.50
0.70%
SIX Swiss Exchange, Nov 02, 05:30 pm CET.
Closed.
Industry
Galderma Target price 2026 - Analyst rating & recommendation
Powered by
Galderma Classifications & Recommendation
Buy
87%
Hold
13%
Galderma Price Target
| Target Price | CHF214.20 |
| Price | CHF191.50 |
| Potential | 11.85% |
| Number of Estimates | 19 |
| 19 Analysts have issued a price target Galderma 2027 . The average Galderma target price is CHF214.20. This is 11.85% higher than the current stock price. The highest price target is CHF273.00 42.56% , the lowest is CHF152.26 20.49% . | |
| A rating was issued by 23 analysts: 20 Analysts recommend Galderma to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2027 of 11.85% . Most analysts recommend the Galderma stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion CHF | ??? | ??? |
| ??? | ??? | |
| EBITDA Margin | ??? | ??? |
| ??? | ??? |
20 Analysts have issued a sales forecast Galderma 2026 . The average Galderma sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
18 Analysts have issued an Galderma EBITDA forecast 2026. The average Galderma EBITDA estimate is
. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | ??? | ??? |
| ??? | ??? | |
| P/E | ??? | |
| EV/Sales | ??? |
Current Galderma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Sep 21 2026 |
| ODDO BHF |
Buy
➜
Buy
|
Unchanged | Sep 21 2026 |
| BNP PARIBAS |
Outperform
➜
Outperform
|
Unchanged | Aug 31 2026 |
| BERENBERG |
Buy
➜
Buy
|
Unchanged | Aug 04 2026 |
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Jul 08 2026 |
| JEFFERIES |
Buy
➜
Buy
|
Unchanged | Jul 07 2026 |
| H.C. WAINWRIGHT & CO., LLC |
Buy
➜
Buy
|
Unchanged | Jul 02 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Sep 21 2026 |
|
Unchanged
ODDO BHF:
Buy
➜
Buy
|
Sep 21 2026 |
|
Unchanged
BNP PARIBAS:
Outperform
➜
Outperform
|
Aug 31 2026 |
|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Aug 04 2026 |
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Jul 08 2026 |
|
Unchanged
JEFFERIES:
Buy
➜
Buy
|
Jul 07 2026 |
|
Unchanged
H.C. WAINWRIGHT & CO., LLC:
Buy
➜
Buy
|
Jul 02 2026 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
